Core Viewpoint - Tenax Therapeutics has appointed Gillian Andor as Vice President of Clinical Operations to support its Phase 3 program for oral levosimendan (TNX-103) targeting pulmonary hypertension due to heart failure with preserved ejection fraction [1][2][3] Group 1: Appointment and Role - Gillian Andor will lead the expanding Clinical Operations function at Tenax Therapeutics [2] - The appointment comes at a critical time as the company is enrolling patients in the Phase 3 LEVEL study and preparing for a second pivotal study [3] Group 2: Experience and Background - Ms. Andor has over 20 years of experience in Clinical Operations, previously serving as Interim Head of Clinical Development Operations at Noema Pharma [3] - She has a strong track record, including leading global clinical development programs at Sage Therapeutics, resulting in successful NDA submissions for Zulresso and Zurzuvae [3] - Ms. Andor also contributed to the NDA and approval of Linzess for IBS-C during her tenure at Ironwood Pharmaceuticals [3] Group 3: Inducement Equity Award - Tenax Therapeutics issued an inducement equity award to Ms. Andor consisting of an option to purchase 250,000 shares of common stock at an exercise price of $6.44 [5] - The award will vest in four equal annual installments, contingent on her continued employment [5] Group 4: Company Overview - Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company focused on cardiovascular and pulmonary diseases with high unmet medical needs [6] - The company owns global rights to develop and commercialize levosimendan and may resume developing its oral formulation of imatinib [6]
Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations